Last update 11 Jul 2024

Rituximab-Pvvr

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
RUXIENCE, Rituximab biosimilar, Rituximab biosimilar (Pfizer)
+ [4]
Target
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects
+ [1]
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
Regulation-
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
-Rituximab-Pvvr

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
CD20 Positive B-Cell Non-Hodgkin Lymphoma
NO
01 Apr 2020
CD20 Positive B-Cell Non-Hodgkin Lymphoma
EU
01 Apr 2020
CD20 Positive B-Cell Non-Hodgkin Lymphoma
LI
01 Apr 2020
CD20 Positive B-Cell Non-Hodgkin Lymphoma
IS
01 Apr 2020
Chronic lymphocytic leukaemia refractory
NO
01 Apr 2020
Chronic lymphocytic leukaemia refractory
IS
01 Apr 2020
Chronic lymphocytic leukaemia refractory
LI
01 Apr 2020
Chronic lymphocytic leukaemia refractory
EU
01 Apr 2020
Chronic Lymphocytic Leukemia
EU
01 Apr 2020
Chronic Lymphocytic Leukemia
LI
01 Apr 2020
Chronic Lymphocytic Leukemia
IS
01 Apr 2020
Chronic Lymphocytic Leukemia
NO
01 Apr 2020
Rheumatoid Arthritis
LI
01 Apr 2020
Rheumatoid Arthritis
IS
01 Apr 2020
CD20 positive B-Cell Lymphoma
JP
20 Sep 2019
CD20 positive Non-Hodgkin Lymphoma
JP
20 Sep 2019
CD20 Positive B-Cell Chronic Lymphocytic Leukemia
US
23 Jul 2019
Granulomatosis With Polyangiitis
US
23 Jul 2019
Microscopic Polyangiitis
US
23 Jul 2019
Non-Hodgkin Lymphoma
US
23 Jul 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CD20 positive Follicular LymphomaPhase 1
MX
30 Sep 2014
CD20 positive Follicular LymphomaPhase 1
ZA
30 Sep 2014
CD20 positive Follicular LymphomaPhase 1
US
30 Sep 2014
CD20 positive Follicular LymphomaPhase 1
UA
30 Sep 2014
CD20 positive Follicular LymphomaDiscovery
IT
30 Sep 2014
CD20 positive Follicular LymphomaDiscovery
PL
30 Sep 2014
CD20 positive Follicular LymphomaDiscovery
FR
30 Sep 2014
CD20 positive Follicular LymphomaDiscovery
GE
30 Sep 2014
CD20 positive Follicular LymphomaDiscovery
AT
30 Sep 2014
CD20 positive Follicular LymphomaDiscovery
RU
30 Sep 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
394
(khkbkwzdwc) = ponroiqlwg dtcpbwucsi (tzynagsczt )
-
01 Apr 2020
Rituximab Reference Product (MabThera®)
(khkbkwzdwc) = ibrchlypna dtcpbwucsi (tzynagsczt )
Phase 3
CD20 positive Follicular Lymphoma
First line
CD20 Positive
394
(syvurbyhox) = dvqnahxvyh gajxrbkljw (zjhuuqihme )
Similar
29 Nov 2018
(syvurbyhox) = tdwdtxqbug gajxrbkljw (zjhuuqihme )
Phase 3
394
sijgozjkus(lbnfzimrbg) = vshacbpaqy lqgxbrvagx (yxiiikrwdc, kimfbozwrt - vmwwrcpehm)
-
30 Oct 2018
Not Applicable
16
(oqpjgrgryl) = pdobyeysla mkghwovows (nqowtfiuhd )
-
21 May 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free